Jing FJ - Search Results

1

Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.

Guo Q, Jing FJ, Xu W, Li X, Li X, Sun JL, Xing XM, Zhou CK, Jing FB. Guo Q, et al. Among authors: jing fj. Aging (Albany NY). 2019 Dec 31;12(1):80-105. doi: 10.18632/aging.102598. Epub 2019 Dec 31. Aging (Albany NY). 2019. PMID: 31895687 Free PMC article.

2

Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins.

Guo Q, Jing FJ, Qu HJ, Xu W, Han B, Xing XM, Ji HY, Jing FB. Guo Q, et al. Among authors: jing fj. Biomed Res Int. 2019 Feb 20;2019:4390839. doi: 10.1155/2019/4390839. eCollection 2019. Biomed Res Int. 2019. PMID: 30915355 Free PMC article.

3

Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway.

Liu X, Guo Q, Jing F, Zhou C, Xiu T, Shi Y, Jing F. Liu X, et al. Cancer Manag Res. 2021 Jun 4;13:4483-4495. doi: 10.2147/CMAR.S300515. eCollection 2021. Cancer Manag Res. 2021. PMID: 34113174 Free PMC article.

4

CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells.

Xiu T, Guo Q, Jing F, Shi Y, Jing F. Xiu T, et al. Transl Cancer Res. 2022 Aug;11(8):2487-2500. doi: 10.21037/tcr-22-345. Transl Cancer Res. 2022. PMID: 36093528 Free PMC article.

5

Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer.

Shi Y, Guo Q, Jing F, Shang X, Zhou C, Jing F. Shi Y, et al. Transl Cancer Res. 2023 Oct 31;12(10):2823-2836. doi: 10.21037/tcr-23-435. Epub 2023 Sep 28. Transl Cancer Res. 2023. PMID: 37969369 Free PMC article.

6

Deciphering the role of non-coding RNAs involved in sorafenib resistance.

Jing F, Shi Y, Jiang D, Li X, Sun J, Zhang X, Guo Q. Jing F, et al. Heliyon. 2024 Apr 13;10(8):e29374. doi: 10.1016/j.heliyon.2024.e29374. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38644890 Free PMC article.

7

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.

Wang Y, Xue H, Song W, Xiao S, Jing F, Dong T, Wang L. Wang Y, et al. Hematol Oncol. 2022 Oct;40(4):617-625. doi: 10.1002/hon.2979. Epub 2022 Feb 23. Hematol Oncol. 2022. PMID: 35165928 Free PMC article.

8

Genetic Polymorphisms in NLRP3 Inflammasome-Associated Genes in Patients with B-Cell Non-Hodgkin's Lymphoma.

Liu ZH, Zhang L, Jing FJ, Xiao SX, Gao Y, Bian HY, Zhao X. Liu ZH, et al. Among authors: jing fj. J Inflamm Res. 2021 Nov 1;14:5687-5697. doi: 10.2147/JIR.S329090. eCollection 2021. J Inflamm Res. 2021. PMID: 34754215 Free PMC article.

9

BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.

Jing FJ, Liang J, Liang ZY, Meng C, Long W, Li XY, Lin YS. Jing FJ, et al. Chin Med J (Engl). 2013 Aug;126(16):3013-8. Chin Med J (Engl). 2013. PMID: 23981603

10

Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies.

Han Z, Xu H, Zhao M, Jing F, Xue H, Xiao S. Han Z, et al. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):e77-e88. doi: 10.1016/j.clml.2021.08.013. Epub 2021 Aug 31. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34593361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters